OnePin Peptide Library · Weight
HGH Frag 176-191
HGH Fragment 176-191 · Lipolytic Fragment · Frag 176-191
HGH Frag 176-191 is the native 16-amino-acid C-terminal fragment of human growth hormone (residues 176-191), corresponding to a beta-turn region of the parent molecule that contains the lipolytic activity of GH without the broader anabolic, glycemic, or growth-promoting effects of full-length GH. The native frag is a research-only compound and is the precursor / parent structure to AOD-9604 (Anti-Obesity Drug 9604), which is a stabilized version with an added N-terminal tyrosine for enhanced stability and potency.
Inject fasted morning and/or pre-workout. Reconstitute with bacteriostatic water; refrigerate. 30-60 minute half-life means timing relative to fasted-state cardio matters. The native fragment is less stable than AOD-9604 - use within 14-21 days post-reconstitution.
Start here. Every protocol below is ordered lowest-first. Begin at the smallest effective dose, hold about a week to assess tolerance, and step up only if needed.
How it works
HGH Frag 176-191 binds the beta-3 adrenergic receptor (β3-AR) on adipocytes and activates the lipolytic cascade similar to other β3 agonists, while also modulating expression of lipid-metabolism genes via mechanisms not fully characterized.
β3-Adrenergic Receptor Activation
Binds β3-AR on white and brown adipocytes, activating Gs/cAMP/PKA cascade. Hormone-sensitive lipase (HSL) is phosphorylated and translocated to lipid droplets, hydrolyzing triglycerides into free fatty acids and glycerol.
Lipogenesis Suppression
Reduces expression of lipogenic enzymes (acetyl-CoA carboxylase, fatty acid synthase) - net opposes new fat storage even in caloric surplus contexts.
GH Activity Selectivity
Despite originating from GH, the fragment does NOT bind the GH receptor and does NOT raise IGF-1. This eliminates the insulin antagonism, edema, and growth-promoting concerns of intact GH while retaining the lipolytic action.
Met-Containing
The native sequence contains methionine residues. NEVER co-store with copper-conjugated peptides (GHK-Cu) - copper drives oxidation of Met to methionine sulfoxide, degrading the peptide.
Stability vs AOD-9604
The native fragment is less stable than AOD-9604 (which has an added N-terminal tyrosine). Native frag should be reconstituted only when needed and stored cold; AOD-9604 has better shelf stability.
Short Plasma Half-Life
~30-60 minutes plasma; functional lipolytic effect 2-4 hours per dose. Daily dosing typical, often split AM and pre-workout.
What to expect
Week 1-2: minimal subjective effect. Lipolytic effect is silent at the cellular level.
Week 4-6: in caloric deficit, may marginally accelerate fat loss vs diet alone.
Week 8-12: cumulative body composition reflects diet + cardio + drug. Standalone effect likely modest based on AOD-9604 clinical data.
Evidence
Interactions & stacking
What's safe to combine, and what belongs in a separate pin.
Keep separate
Side effects & safety
Commonly reported
- Injection site reaction (mild)
- Mild headache (early doses)
- Possible mild tachycardia (β3-AR mediated, typically mild)
Less common & notes
- Mild gastrointestinal upset.
- Theoretical β3-AR-mediated cardiovascular effects (mild tachycardia, palpitations) - typically mild.
- Long-term safety beyond Phase 2b AOD-9604 data is uncharacterized for native HGH frag.
- Methionine oxidation reduces potency over storage time - users dose escalating may be compensating for degraded peptide rather than gaining efficacy.
- Allergic reaction to peptide is rare.
Pharmacokinetics
Storage. Lyophilized vial: refrigerate (2-8°C / 36-46°F) or freeze (-20°C) for long-term storage. After reconstitution with bacteriostatic water: refrigerate, use within 14-21 days. The native fragment is less stable than AOD-9604 - methionine residues are oxidation-sensitive. Light-sensitive. Do NOT shake. Discard if cloudy, discolored, or beyond use-by window.
Regulatory status
Not FDA-approved for any indication. Native HGH Frag 176-191 never advanced to clinical trials. The stabilized derivative AOD-9604 advanced through Phase 2b trials in obesity (Metabolic Pharmaceuticals) but failed primary endpoint and was abandoned. Sold only as research chemical from peptide-supply vendors. WADA prohibited under class S2 (peptide hormones, growth factors). Sale for human use is illegal under FDA regulation.
Put it to work
Calculate, log & track
Open HGH Frag 176-191 straight into OnePin with your vial and dose pre-filled, then let it handle the syringe math and remind you before the vial runs out.
Open HGH Frag 176-191 in the app →Go deeper
The guide & community
The complete HGH Frag 176-191 walkthrough, real protocol discussion and coaching live inside the BlessUp community on Skool.
Join the community ↗